Roivant and Priovant reported positive Phase 3 results for Lisraya (an immune-modifying pill) in non-infectious uveitis, extending the drug’s clinical momentum beyond its earlier dermatomyositis approval. The two Phase 3 studies enrolled 371 patients and, according to the company, showed placebo-separated effectiveness outcomes. Roivant said it plans to seek an FDA expansion decision in the first half of 2027, potentially expanding Lisraya into a much larger inflammatory-eye market. Analysts and clinicians will now focus on durability of response, safety across broader patient phenotypes, and how results compare with existing biologic and small-molecule standards. The read-through for the sector is direct: immune-modulating oral therapies continue to capture interest where injection burden, payer flexibility, and chronic treatment adherence are key differentiators.